About the Company:
Indegene Limited, a frontrunner in digital solutions tailored for the life sciences sector, is poised to mark a significant milestone through its Initial Public Offering (IPO). Since its inception in 1998, the company has played a pivotal role in offering essential services across various dimensions of pharmaceutical and healthcare operations.
Indegene Limited boasts a comprehensive suite of digital solutions meticulously crafted to cater to the intricate needs of the life sciences industry. Its offerings span the entire pharmaceutical lifecycle, encompassing crucial stages such as drug development, clinical trials, regulatory adherence, and marketing support. With a diverse portfolio, Indegene has solidified its position as a reliable ally for industry leaders in search of groundbreaking solutions.
Service Offerings
- Enterprise Commercial Solutions: Enhancing commercial operations efficiency through cutting-edge digital platforms.
- Omnichannel Activation: Amplifying customer engagement and brand presence across diverse channels.
- Enterprise Medical Solutions: Facilitating seamless management of medical affairs and regulatory compliance.
- Enterprise Clinical Solutions and Consultancy: Providing strategic guidance and support throughout the clinical development journey.
Subsidiary:
DT Associates Limited Operating under the umbrella of Indegene Limited, DT Associates Limited serves as a specialized consultancy arm focusing on digital transformation within the life sciences realm. Through its brand, "DT Consulting," the subsidiary aids companies in navigating the intricate landscape of digital evolution, ensuring sustained growth and competitive edge.
Accolades and Recognitions
Indegene Limited's unwavering commitment to excellence has garnered recognition, exemplified by the prestigious Platinum Level award bestowed upon it at the 2023 Healthy Workplace Conference and Awards. This accolade underscores the company's dedication to nurturing a healthy and vibrant work culture, aligning with global standards of excellence.
Objectives of the Issue
The IPO proceeds are earmarked for strategic initiatives aimed at bolstering Indegene Limited's market position. Key objectives include:
- Debt Repayment: Addressing indebtedness within Material Subsidiaries to optimize financial stability.
- Capital Expenditure: Allocating funds to meet crucial capital requirements essential for operational expansion and innovation.
- General Corporate Purposes: Utilizing funds for organic growth strategies and potential acquisitions to enhance market penetration and presence.
Summary of Financial Information
| Period Ended | 31-Dec-23 | 31-Mar-23 | 31-Mar-22 | 31-Mar-21 |
|---|---|---|---|---|
| Assets | 2,518.15 | 2,203.87 | 1,353.47 | 596.04 |
| Revenue | 1,969.75 | 2,364.10 | 1,690.50 | 996.92 |
| Profit After Tax | 241.9 | 266.1 | 162.82 | 149.41 |
| Net Worth | 1,327.00 | 1,063.72 | 763.9 | 324.51 |
| Reserves and Surplus | 1,282.65 | 1,019.43 | 763.55 | 324.19 |
| Total Borrowing | 399.33 | 394.34 | 18.24 | 24.76 |
No Listed Peers:
The company asserts that there are no other listed peers, either in India or globally, that operate similarly. Its unique business model affords it a near-monopoly in its industry.
Key Details of Indegene Limited IPO
- IPO Dates: 6 to 8 May 2024
- Price Band: Rs. 430 to Rs. 452 per share
- Lot Size: 33 Shares
- Issue Size: Rs. 1,841.76 Crs (Fresh Issue: Rs. 760 Cr.)
- Listing Date: 13 May, 2024
- Retail Quota: 35%
- GMP: Rs. 240 (Only for information)
Note: For additional information & risk factors please refer to the Red Herring Prospectus
Join our WhatsApp Group for Trading/Investment ideas & Market Updates 👇
Disclaimer: We are not SEBI registered. All the views are personal and only for educational purposes. Do your due diligence before making any trading or investing decisions. The data provided in this blog post is for illustrative purposes only and does not constitute financial advice. Always consult with a qualified financial advisor before making investment decisions.
